AMLX Q2 2024 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$1M-101.0% YoY

Gross Profit

-$9M845.5% margin

Operating Income

-$53M5223.4% margin

Net Income

-$73M7106.5% margin

EPS (Diluted)

$-1.07

QoQ Revenue Growth

-101.2%

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$67M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$332M

Total Liabilities

$71M

Stockholders' Equity

$261M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$1M	$98M	-101.0%
Gross Profit	-$9M	$93M	-109.3%
Operating Income	-$53M	$20M	-364.5%
Net Income	-$73M	$22M	-429.3%